Hypomanic episode

Article written and reviewed by Dr Luca Moretti

A hypomanic episode is an episodic affective syndrome characterized by a clearly recognizable change in mood accompanied by an abnormal increase in activity or energy and additional cognitive and behavioral manifestations of activation. It should not simply be regarded as “mild mania”: hypomania and mania share much of their phenomenology but are distinguished primarily by functional severity, the need for intensive treatment, and the presence of psychosis. By definition, hypomania does not cause the marked social or occupational impairment characteristic of mania, does not require hospitalization or intensive treatment to prevent harm, and is not accompanied by delusions or hallucinations.

DSM-5-TR and ICD-11 describe very similar presentations but use operational thresholds that do not completely overlap. DSM-5-TR requires at least four consecutive days of abnormally and persistently elevated, expansive, or irritable mood associated with a persistent increase in activity or energy. The 2024 ICD-11 CDDR instead uses a more flexible formulation: mood disturbance and increased activity or energy must be present for most of the day, nearly every day, for at least several days, accompanied by several hypomanic manifestations and a significant change from usual behavior.

The episode must be conceptually distinguished from the disorder in which it occurs. In DSM-5-TR, bipolar II disorder requires at least one hypomanic episode and at least one major depressive episode, in the absence of a history of a manic episode. A hypomanic episode may nevertheless also occur during the course of bipolar I disorder, in which diagnosis is based on the current or historical presence of at least one manic episode. In ICD-11, bipolar II disorder requires a history of hypomanic and depressive episodes and the absence of previous manic or mixed episodes.

Epidemiologically as well, it is therefore incorrect to use the prevalence of bipolar II disorder as though it represented the prevalence of hypomanic episodes. The frequency of isolated hypomania varies considerably according to the definition, diagnostic instrument, and duration threshold used. In the US National Comorbidity Survey Replication, conducted according to DSM-IV criteria, lifetime prevalence was 1.1% for bipolar II disorder and 1.0% for bipolar I disorder; in the World Mental Health Surveys, pooled estimates were 0.4% and 0.6%, respectively. These are prevalences of the disorders, not of episodes, but they document the epidemiological context in which hypomania is most commonly recognized.

Epidemiological identification of hypomania is particularly complex because many people do not perceive the period of activation as pathological. A phase characterized by greater energy, confidence, productivity, and sociability may be remembered positively and not reported spontaneously during an assessment conducted for depression. For this reason, bipolar II disorder may initially be recognized as recurrent depressive disorder when the history does not systematically explore previous episodic changes in mood and activity.

Etiology, pathogenesis and pathophysiology

A hypomanic episode does not have a single etiological cause valid for all patients. When it occurs spontaneously within a bipolar disorder, it reflects a complex vulnerability involving genetic, neurobiological, circadian, and environmental factors. When a hypomanic syndrome is instead the direct pathophysiological consequence of a substance, medication, or medical condition, diagnostic classification must recognize that etiological relationship rather than automatically attributing the presentation to a primary bipolar disorder.

Bipolar disorder has a strong hereditary component but a polygenic architecture. Genome-wide studies have identified numerous susceptibility loci and indicate the involvement of many common variants, each with a modest individual effect. Associations involve, among others, genes related to neuronal signaling and synaptic function, but no genetic variant can diagnose hypomania or deterministically predict its occurrence.

A family history of bipolar disorder is therefore an important risk factor but not a sufficient cause. The probability of developing the disorder emerges from the interaction between genetic predisposition and multiple environmental and biological factors. The presence of relatives with bipolar disorder should heighten diagnostic attention, especially in an apparently depressed patient who reports previous periods of decreased need for sleep, increased energy, or unusually expansive behavior.

The sleep-circadian system is one of the main pathophysiological elements studied in bipolar disorders. Reduced sleep, schedule disruption, shift work, jet lag, and other disturbances of social rhythms may precede or accompany activation episodes in vulnerable individuals. The relationship is bidirectional: decreased need for sleep is itself a symptom of hypomania and may at the same time amplify mood instability.

Decreased need for sleep must be distinguished from insomnia. In the former, the individual sleeps less than usual and still reports feeling rested and energetic; with insomnia, the person wants to sleep but cannot and frequently experiences fatigue. This distinction is clinically important because true decreased need for sleep has a more specific significance for manic or hypomanic activation.

Studies of neurotransmitter systems suggest involvement of dopaminergic, glutamatergic, and GABAergic pathways and their interactions with serotonergic and noradrenergic systems. Contemporary models do not, however, support the existence of a simple “dopamine excess” as a universal explanation for hypomania. Available data derive largely from studies of bipolar disorder, comparisons between mood states, and treatment effects and do not identify a necessary and sufficient abnormality.

Intracellular changes in neuroplasticity, mitochondrial function, calcium homeostasis, and signaling mechanisms have been proposed as components of bipolar vulnerability. The fact that drugs such as lithium and some antipsychotics act on numerous intracellular systems supports the complexity of the pathophysiology but does not allow reconstruction of a single molecular cascade responsible for the episode.

Similarly, group-level alterations in inflammatory markers, oxidative stress, and regulation of the hypothalamic-pituitary-adrenal axis have been documented. These associations are heterogeneous and may be influenced by mood state, comorbidities, sleep, smoking, obesity, medications, and numerous other confounders. None of these parameters currently represents a clinical biomarker of hypomania.

Neuroimaging studies conducted in bipolar disorder have identified average differences in cortical and subcortical structures, including frontal, temporal, hippocampal, and thalamic regions. Large analyses from the ENIGMA consortium have nevertheless shown distributed effects and considerable overlap between patients and controls. Brain magnetic resonance imaging therefore cannot diagnose a hypomanic episode.

From a functional perspective, hypomanic activation can be interpreted as the result of altered regulation of networks governing reward, motivation, salience, inhibitory control, and emotional processing. Increased reward drive associated with reduced control over consequences provides a plausible model for explaining increased goal-directed activity, grandiosity, and risky behavior, but it remains a population-level model rather than an individual diagnostic mechanism.

Antidepressants may be temporally associated with the emergence of hypomanic symptoms in vulnerable people. The causal relationship must, however, be interpreted precisely. In DSM-5-TR, a full hypomanic syndrome that emerges during antidepressant treatment and persists beyond the physiological effect of the treatment may be considered evidence of a true hypomanic episode; simple agitation, irritability, or transient presence of one or two symptoms after starting an antidepressant is not sufficient to infer bipolarity.

Stimulant substances such as cocaine and amphetamines can also produce euphoria, insomnia, increased energy, talkativeness, grandiosity, and impulsivity. In these cases, the temporal sequence between use, intoxication or withdrawal, and symptoms is fundamental for determining whether the presentation is a substance-induced disorder or a coincident spontaneous episode.

Among medications capable of producing activation syndromes in susceptible patients are corticosteroids and certain dopaminergic drugs. Here too, a temporal association should not automatically be converted into causality: the presentation must be compared with previous spontaneous episodes, dosage, duration of exposure, discontinuation, and persistence of symptoms.

A hypomanic presentation may also be secondary to neurological or endocrine conditions. Focal brain disease, traumatic brain injury, demyelinating diseases, some forms of epilepsy, and thyroid dysfunction enter the differential diagnosis especially when onset is atypical, late, or accompanied by neurological signs. There is, however, no panel of organic tests that should be performed indiscriminately in every patient.

The postpartum period is a phase of particular vulnerability to mood disturbances in people predisposed to bipolar disorder. Sleep changes, abrupt endocrine shifts, and psychosocial stress may contribute to destabilization. Postpartum onset of decreased need for sleep, acceleration, euphoria, or irritability should be assessed carefully because it may precede more severe presentations.

Stress and life events may also contribute to onset, but the relationship is probabilistic. Not every episode is preceded by an identifiable event, and not every person exposed to stress develops hypomania. The model most consistent with the evidence therefore considers the episode the result of individual vulnerability upon which changes in sleep, circadian rhythms, medications, substances, and environmental exposures act.

Clinical manifestations

Clinical assessment begins with the history, but during hypomania the patient may perceive no problem and may present for entirely different reasons, often during a subsequent depressive phase. It is therefore necessary to reconstruct retrospectively distinct periods in which mood, energy, sleep, and behavior were clearly different from the usual state.

The question should not be limited to asking whether the patient has ever been “euphoric.” Some episodes are dominated by irritability rather than euphoria, while others are remembered mainly as periods of exceptional energy, productivity, greater confidence, reduced need for sleep, and intense socializing. The central element is an episodic change from the individual’s baseline functioning.

The patient may report a feeling of particular well-being, confidence in their abilities, and ease in undertaking activities that would normally require more effort. Increased self-esteem may remain within nondelusional limits or assume features of clear grandiosity, but if the presentation reaches psychotic intensity the classification changes from hypomania to mania.

Decreased need for sleep is one of the most characteristic symptoms. The person may sleep only a few hours compared with their usual amount, awaken spontaneously, and immediately begin new activities without feeling sleepy. The clinician must distinguish this phenomenon from anxious or depressive insomnia, in which lack of sleep is unwanted and is generally associated with fatigue.

Speech may become faster, more abundant, and difficult to interrupt. The person talks more than usual, makes phone calls or sends messages with unusual frequency, repeatedly joins conversations, and may appear especially witty or brilliant. In more evident forms, true pressured speech develops.

At the same time, subjective acceleration of thought may occur. Ideas follow one another rapidly, and the patient may report a sense that the mind is particularly fast or productive. Flight of ideas is possible, but very severe thought disorganization should prompt consideration of mania, psychosis, substances, or other conditions.

Distractibility results from the ease with which irrelevant environmental stimuli capture attention. During the interview, the patient may interrupt the conversation to comment on noises, people, or objects in the room and may start numerous activities without completing them.

Increased goal-directed activity may involve work, study, sports, social relationships, sexuality, artistic activities, entrepreneurial projects, or household initiatives. Some people temporarily produce results above their usual standard, and this apparent positivity can itself make the episode difficult to recognize.

Increased activity need not, however, be effective. The person may start many projects simultaneously, continually change goals, or overestimate their capabilities, with progressive dispersion of time and resources. Distinguishing greater productivity from pathological activation depends on the overall symptom pattern and the deviation from usual behavior.

Potentially risky activities may include disproportionate spending, poorly considered investments, reckless driving, gambling, substance use, or unusual sexual behavior. In hypomania, these behaviors must not produce the marked impairment that would define mania, but they may still have clinically relevant consequences.

Greater sociability may manifest as ease in talking to strangers, increased contacts, excessively familiar or disinhibited behavior, and increased sexual desire. The boundary between a temperamental trait and an episode depends mainly on temporal discontinuity: hypomania constitutes a circumscribed change from the person’s usual mode of functioning.

When irritability predominates, the patient may appear impatient, argumentative, intolerant of contradiction, and easily frustrated. Irritability alone, however, is highly nonspecific and does not permit a diagnosis of hypomania without the concomitant change in energy or activity and the other syndromic features.

Mixed features may be present, meaning depressive symptoms during a hypomanic episode. Depressed mood, anhedonia, fatigue, guilt, or thoughts of death may coexist with activation and acceleration. This combination is clinically important because it may be associated with greater distress and risk than classic euphoric hypomania.

The mental status examination may reveal clothing that is more conspicuous or carefully selected than usual, lively gestures, greater familiarity, increased psychomotor activity, rapid speech, expansive or irritable affect, and accelerated thinking. Orientation and basic cognitive functions are generally preserved, while judgment and awareness of the behavioral change may be reduced.

Psychosis is incompatible with the DSM diagnosis of a hypomanic episode, and ICD-11 likewise excludes delusions and hallucinations from the definition of hypomania. If delusions or hallucinations occur during an apparently hypomanic presentation, the episode must be reassessed as manic or attributed to another appropriate diagnosis.

Obtaining information from family members, partners, or people who know the person well has particular value. The patient may not recognize their behavior as abnormal, whereas those living with them may clearly describe reduced sleep, increased activity, talkativeness, or changes in money management.

Diagnosis in children and adolescents requires particular caution. Irritability, sleep changes, impulsivity, and increased activity may be physiological or may belong to ADHD and other disorders. The episodic nature, simultaneous change in mood and energy, and change from previous functioning are therefore fundamental.

Assessment and diagnosis

The diagnosis of a hypomanic episode is clinical. There are no laboratory tests, genetic tests, neuroimaging studies, EEG findings, or biomarkers capable of confirming the presentation in an individual patient. The diagnostic process must establish whether an episode is truly present, determine its severity, reconstruct the longitudinal mood history, and verify that the symptoms do not depend directly on substances, medications, or medical illnesses.

The first step is to define baseline functioning. An individual who is normally expansive, energetic, or physiologically needs little sleep should not be classified as hypomanic simply because these characteristics are present. An unequivocal change, temporally circumscribed and different from the usual way of being and behaving, must be demonstrated.

According to DSM-5-TR, a hypomanic episode is defined by official diagnostic criteria requiring both a change in mood and an increase in activity or energy.

To identify a hypomanic episode according to DSM-5-TR, a distinct period of at least four consecutive days must be documented, with abnormally elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, present for most of the day nearly every day, associated with at least three of the following symptoms, or at least four when the mood is exclusively irritable.

• Increased self-esteem or grandiosity.
• Decreased need for sleep, with a feeling of being rested despite a shorter sleep duration.
• Greater talkativeness than usual or internal pressure to keep talking.
• Flight of ideas or the subjective experience of racing thoughts.
• Distractibility.
• Increased goal-directed activity socially, at work, at school, or sexually, or psychomotor agitation.
• Excessive involvement in potentially harmful activities with a high probability of negative consequences.

Additional conditions must be met beyond the symptom threshold. The episode must be associated with an unequivocal change in functioning that is uncharacteristic of the person when asymptomatic; the disturbance and change must be observable by others; the presentation must not be severe enough to cause marked social or occupational impairment or require hospitalization; and psychotic features must not be present.

The presentation must also not be attributable to the physiological effects of a substance. A full syndrome arising during antidepressant treatment that persists beyond the physiological effect of the treatment may nevertheless contribute to the diagnosis according to DSM-5-TR. This principle does not justify automatically classifying transient irritability, agitation, or a few activation symptoms after starting an antidepressant as hypomania.

ICD-11 CDDR differs from the DSM mainly in its less rigidly numerical approach. It requires both a persistent elevation of mood or increased irritability and an increase in activity or energy, present for most of the day nearly every day for at least several days, accompanied by several characteristic manifestations such as increased talkativeness, racing thoughts, increased self-esteem, decreased need for sleep, distractibility, impulsivity, or increased sexuality, sociability, and goal-directed activity.

In ICD-11 as well, the change must be significant and recognizable compared with usual behavior, must not be explained by substances, medications, or medical conditions, must not meet the requirements for a mixed episode, and must not cause marked impairment or be accompanied by delusions or hallucinations. The DSM duration of four days should therefore not be presented as a universal rule valid for both diagnostic systems.

Once the episode has been recognized, the underlying disorder must be established. A single hypomanic episode without a history of depression, mania, or other conditions permitting longitudinal classification does not automatically equate to bipolar II disorder. In the DSM, bipolar II requires at least one hypomanic episode and at least one major depressive episode and no previous manic episode.

Historical assessment for previous mania is essential because even one manic episode changes the diagnosis to bipolar I disorder. The clinician should therefore explore psychiatric hospitalizations, psychosis, periods of severe disorganization, catastrophic spending, risky behavior, and activation phases that caused much greater impairment than the current episode.

It is equally necessary to reconstruct depressive episodes. In bipolar II disorder, depressive phases often produce the greatest burden of distress and bring the patient to treatment, while previous hypomanic periods may be underestimated or perceived as periods of particular well-being.

Scales such as the Young Mania Rating Scale can be useful for quantifying the severity of activation symptoms and following their course, while questionnaires such as the Mood Disorder Questionnaire may contribute to screening for bipolarity. Neither instrument is an independent diagnostic test, and results must be integrated with the clinical interview.

Laboratory tests are requested in a targeted manner when the history, onset, physical examination, or treatment plan makes them appropriate. Complete blood count, electrolytes, renal and liver function, TSH, and toxicology testing may be useful in specific contexts; in people with pregnancy potential, pregnancy testing is particularly important before certain treatments.

Neuroimaging and EEG are not routine tests for hypomania. They may become indicated when onset is late or sudden, when neurological deficits, atypical cognitive changes, seizures, head trauma, or other features suggesting a secondary neurological condition are present.

The main differential diagnosis is a manic episode. Symptoms may be qualitatively identical, and the distinction depends on severity: marked impairment, need for intensive treatment or hospitalization to prevent harm, or the presence of psychosis place the presentation within mania.

ADHD may cause increased activity, distractibility, impulsivity, and talkativeness, but it tends to have a persistent course with onset during the developmental period, rather than clearly demarcated periods of change in mood and energy. ADHD and bipolar disorder may nevertheless coexist.

Personality disorders characterized by affective instability may manifest rapid mood swings and impulsivity. In these cases, changes are generally more closely reactive to the interpersonal context and form part of a persistent pattern, whereas a hypomanic episode requires a sustained syndromic change distinct from usual functioning.

Cocaine, amphetamines, other stimulants, medications, and medical conditions should be assessed through medication and toxicological history, temporal relationship, and any specific investigations. The decisive diagnostic point is not simply documenting that the patient uses a substance or medication, but establishing whether it pathophysiologically explains the episode.

Treatment and prognosis

Treatment should not be decided on the label of “hypomanic episode” alone, but on the diagnosis of the underlying bipolar disorder, the severity of activation, the presence of mixed features, behavioral consequences, treatments already taken, and the risk of progression to mania. Hypomania without immediate risks does not automatically require hospitalization or aggressive treatment.

The first step is to assess safety and context. Risky financial or sexual behavior, dangerous driving, substance use, aggression, progressive sleep loss, and rapid escalation of activation should be investigated. If the presentation has already caused marked impairment, requires hospitalization to prevent harm, or includes psychosis, it no longer meets the definition of hypomania and should be managed as mania.

It is essential to identify and correct possible precipitating factors. Regularizing sleep and daily rhythms, reducing stimulants and psychoactive substances, and controlling caffeine and alcohol use may contribute to stabilization. An excessively stimulating environment can worsen activation.

When hypomania emerges during antidepressant therapy, bipolar-disorder guidelines recommend reassessing treatment and generally discontinuing the antidepressant responsible for activation, with the method depending on the drug, treatment duration, and risk of discontinuation symptoms. The treatment change should be accompanied by reassessment of the longitudinal diagnosis.

Guidelines do not provide a specific and universally shared pharmacological hierarchy exclusively for hypomania. NICE addresses mania and hypomania together in its acute recommendations and, when pharmacological treatment is needed, lists antipsychotics such as haloperidol, olanzapine, quetiapine, or risperidone among initial options, taking into account current treatments, preferences, and risk profiles.

CANMAT/ISBD guidelines are based primarily on evidence for acute mania and longitudinal management of bipolar disorder. Lithium and several second-generation antipsychotics are key elements of antimanic treatment when required. In hypomania, however, choice should be proportionate to severity rather than consisting of automatic application of an algorithm for severe mania.

Lithium is one of the principal maintenance treatments for bipolar disorder and is effective in preventing recurrences in selected patients. Before and during treatment, renal and thyroid function should be assessed, serum lithium levels monitored, and attention paid to drug interactions, hydration, and conditions that may alter drug clearance.

Second-generation antipsychotics differ in efficacy across phases of the disorder, metabolic effects, sedation, extrapyramidal symptoms, prolactin effects, and other adverse events. Choice should be individualized, and it is not correct to regard them as interchangeable simply because they belong to the same class.

Valproate has antimanic efficacy, but its use requires particular attention to current regulatory restrictions. In Italy and the European Union, it is contraindicated for treatment of bipolar disorder during pregnancy; in women of childbearing potential, its use is subject to strict pregnancy-prevention measures and specialist reassessment. Since 2024, AIFA and EMA have also introduced specific precautions for men treated with valproate regarding a possible, though not definitively confirmed, reproductive risk.

Psychotherapy does not necessarily replace pharmacotherapy when acute stabilization is required, but psychoeducation, cognitive behavioral therapy, family interventions, and strategies aimed at stabilizing social rhythms may contribute to prevention of recurrences and early recognition of prodromal signs.

A particularly important goal is to teach the patient and close contacts to recognize early changes in sleep, energy, speed of thought, spending, and activity. Intervention in the early stages may prevent a relatively controlled episode from progressing to a more severe condition.

When depressive symptoms are simultaneously present, mixed features should be assessed. These alter the risk profile and may influence pharmacological choice, making it particularly important to avoid uncritical use of antidepressants in bipolar disorder.

The acute phase should be followed by assessment of the need for maintenance treatment. The decision depends on the diagnosis of bipolar I or II disorder, frequency and severity of episodes, previous depressive episodes, suicidal history, comorbidities, and medication response.

The prognosis of an individual hypomanic episode is generally better than that of mania in terms of immediate impairment, but this does not mean that bipolar II disorder is a mild illness overall. Recurrent depressive episodes, mixed features, suicide risk, and interepisode impairment can produce a considerable clinical burden.

The natural duration of the episode varies, and there is no universal remission percentage applicable to an individual patient. The course should be assessed longitudinally, taking treatment, previous episodes, and stability of sleep and circadian rhythms into account.

Some people initially diagnosed with bipolar II disorder may later experience a manic episode, resulting in reclassification as bipolar I disorder. The possibility of this evolution makes it necessary to continue exploring the intensity and consequences of activation phases over time.

Prognosis improves when the patient develops awareness of personal prodromal signs, maintains good adherence, avoids destabilizing substances, and has a shared plan for early intervention. Recovery should be assessed not only as normalization of mood but also as restoration of relational, occupational, and social functioning.

Complications

By definition, hypomania does not cause the marked functional impairment characteristic of mania, but it can still produce negative consequences. “Absence of marked impairment” does not in fact mean complete absence of problems.

Impulsive financial decisions may involve unusual spending, unnecessary purchases, poorly considered investments, or financial commitments that the patient later recognizes as inappropriate. If the consequences become extremely severe, it is necessary to reassess whether the threshold for mania was actually exceeded.

Disinhibition may promote unusual sexual behavior, reduced perception of risk, unprotected sex, or impairment of intimate relationships. Even in the absence of severe immediate disability, such behaviors may have persistent consequences after the episode remits.

Increased activity and decreased need for sleep may lead to progressive sleep deprivation. In a vulnerable person, this may amplify activation, further impair judgment, and contribute to progression toward a more severe syndrome.

Reckless driving, excessively risky sports, and other impulsive behaviors may increase the likelihood of accidents and injuries. Risk should be assessed on the basis of actual behavior rather than simply the number of diagnostic symptoms.

Occupational and interpersonal conflicts may arise from greater assertiveness, irritability, excessive familiarity, or the belief of having superior abilities. A phase initially perceived as productive can therefore gradually impair social functioning.

Increased alcohol or substance use may worsen disinhibition, sleep disturbance, and mood instability. The presence of a comorbid substance-use disorder also makes it more difficult to distinguish spontaneous symptoms from effects of intoxication or withdrawal.

One of the most clinically important developments is progression to mania. When severity increases to the point of causing marked impairment, a need for intensive treatment, or psychosis, classification must change: the presentation is no longer hypomania.

In bipolar disorder, a subsequent transition to a depressive phase may cause much greater suffering than that experienced during hypomania. Patients and families should therefore avoid judging the episode solely on the basis of the subjective pleasantness of the activation phase.

The simultaneous presence of depressive and hypomanic symptoms constitutes a presentation with mixed features and may be associated with greater agitation, impulsivity, and suicide risk. Thoughts of death or self-harming behavior always require specific assessment regardless of the apparent increase in energy.

Finally, treatment-related complications may occur: sedation, metabolic changes, extrapyramidal symptoms, thyroid or renal dysfunction, and other events depend on the drug used. Proper management of hypomania therefore requires not only control of activation but longitudinal monitoring of the balance among efficacy, tolerability, and prevention of recurrence.

Bibliography
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishing. 2022.
2. World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. World Health Organization. 2024.
3. Yatham LN et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 20(2), 2018: 97-170.
4. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Bipolar Disorder. Washington, DC. 2023.
5. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical Guideline CG185. 2014, updated 2025.
6. McIntyre RS et al. Bipolar disorders. Lancet. 396(10265), 2020: 1841-1856.
7. Merikangas KR et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 64(5), 2007: 543-552.
8. Merikangas KR et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 68(3), 2011: 241-251.
9. Mullins N et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 53(6), 2021: 817-829.
10. Stahl EA et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 51(5), 2019: 793-803.
11. Hibar DP et al. Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry. 21(12), 2016: 1710-1716.
12. Hibar DP et al. Cortical abnormalities in adults and adolescents with bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry. 23(4), 2018: 932-942.
13. Grande I et al. Bipolar disorder. Lancet. 387(10027), 2016: 1561-1572.